Covid-19 vaccine marketing roundup: New data bolster case for J&J's single-dose vaccine — report; Germany inks deals with vaccine makers in preparation for future outbreaks
Plagued by concerns around rare blood clots and reports of weaker immune responses, it appeared the fate of Johnson & Johnson’s Covid-19 vaccine was sealed when the CDC recommended back in December that Americans opt for one of the mRNA jabs instead. But new data suggest that the shot could make a comeback.
The CDC recently reported that unvaccinated people were 3.2 times more likely to become infected with Covid than those who received J&J’s single-dose shot, according to a New York Times report. Meanwhile, unvaccinated individuals were only 2.8 times more likely to contract Covid than those vaccinated with two doses of the Moderna shot, and only 2.4 times as likely as those who got two doses of the Pfizer/BioNTech vaccine. And all the vaccines appeared to perform roughly the same among those who’ve been boosted, according to the Times.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
